DNA Topoisomerases, Type II

• 

  Subject Areas on Research

  • A Bacterial Chromosome Structuring Protein Binds Overtwisted DNA to Stimulate Type II Topoisomerases and Enable DNA Replication. 
  • A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells. 
  • A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents. 
  • ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization. 
  • An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo. 
  • Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. 
  • Analysis of cleavage complexes using reactive inhibitor derivatives. 
  • Analysis of the eukaryotic topoisomerase II DNA gate: a single-molecule FRET and structural perspective. 
  • Atp-bound topoisomerase ii as a target for antitumor drugs. 
  • Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli. 
  • Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes. 
  • Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors. 
  • CENP-A and topoisomerase-II antagonistically affect chromosome length. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Casein kinase II copurifies with yeast DNA topoisomerase II and re-activates the dephosphorylated enzyme. 
  • Casein kinase II phosphorylates the eukaryote-specific C-terminal domain of topoisomerase II in vivo. 
  • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 
  • Complex response of breast epithelial cell lines to topoisomerase inhibitors. 
  • DNA topoisomerases. 
  • Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα. 
  • Displacement of D1, HP1 and topoisomerase II from satellite heterochromatin by a specific polyamide. 
  • Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. 
  • Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. 
  • Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site. 
  • Drosophila topoisomerase II-DNA interactions are affected by DNA structure. 
  • Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. 
  • Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. 
  • Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. 
  • Formation and resolution of DNA catenanes by DNA gyrase. 
  • Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. I. In vitro studies. 
  • Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. II. In vivo studies. 
  • Functional cooperation between topoisomerase I and single strand DNA-binding protein. 
  • Functional expression of a Drosophila gene in yeast: genetic complementation of DNA topoisomerase II. 
  • Genetic variability of Bacillus anthracis and related species. 
  • Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons. 
  • Hotspot sites for acridine-induced frameshift mutations in bacteriophage T4 correspond to sites of action of the T4 type II topoisomerase. 
  • Identifying Lys359 as a critical residue for the ATP-dependent reactions of Drosophila DNA topoisomerase II. 
  • Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26. 
  • International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. 
  • Isolation and characterization of the gene encoding Drosophila DNA topoisomerase II. 
  • Knotting of the circular duplex DNA by type II DNA topoisomerase from Drosophila melanogaster. 
  • Linker insertion mutagenesis of Drosophila topoisomerase II. Probing the structure of eukaryotic topoisomerase II. 
  • Localization of RAP1 and topoisomerase II in nuclei and meiotic chromosomes of yeast. 
  • Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. 
  • Loss of a histone deacetylase dramatically alters the genomic distribution of Spo11p-catalyzed DNA breaks in Saccharomyces cerevisiae. 
  • Low levels of DNA polymerase alpha induce mitotic and meiotic instability in the ribosomal DNA gene cluster of Saccharomyces cerevisiae. 
  • Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II. 
  • Monitoring the topoisomerase II DNA gate conformational change with fluorescence resonance energy transfer. 
  • Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). 
  • Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA. 
  • Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. 
  • Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. 
  • Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone. 
  • New mechanistic and functional insights into DNA topoisomerases. 
  • Novel partitioning of DNA cleavage sites for Drosophila topoisomerase II. 
  • Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites. 
  • Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. 
  • Probing conformational changes in human DNA topoisomerase IIα by pulsed alkylation mass spectrometry. 
  • Purification and properties of type II DNA topoisomerase from embryos of Drosophila melanogaster. 
  • Purification of the bacteriophage T4 type II DNA topoisomerase. 
  • Recognition of single-stranded DNA by the bacteriophage T4-induced type II topoisomerase. 
  • Regulation of DNA gyrase operon in Mycobacterium smegmatis: a distinct mechanism of relaxation stimulated transcription. 
  • Regulation of L-selectin-mediated rolling through receptor dimerization. 
  • Regulation of topoisomerase II by phosphorylation: a role for casein kinase II. 
  • Repair of topoisomerase-mediated DNA damage in bacteriophage T4. 
  • Restoration of topoisomerase 2 function by complementation of defective monomers in Drosophila. 
  • Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase. 
  • Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding. 
  • Single strand DNA cleavage reaction of duplex DNA by Drosophila topoisomerase II. 
  • Single-molecule measurements of the opening and closing of the DNA gate by eukaryotic topoisomerase II. 
  • Site-specific recognition of bacteriophage T4 DNA by T4 type II DNA topoisomerase and Escherichia coli DNA gyrase. 
  • Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis. 
  • Structure and activities of Escherichia coli DNA gyrase. 
  • Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II. 
  • Targeting nucleolin for better survival in diffuse large B-cell lymphoma. 
  • The C-terminal 20 Amino Acids of Drosophila Topoisomerase 2 Are Required for Binding to a BRCA1 C Terminus (BRCT) Domain-containing Protein, Mus101, and Fidelity of DNA Segregation. 
  • The additional 165 amino acids in the B protein of Escherichia coli DNA gyrase have an important role in DNA binding. 
  • The composition and morphology of yeast nuclear scaffolds. 
  • The hydrophilic, protease-sensitive terminal domains of eucaryotic DNA topoisomerases have essential intracellular functions. 
  • The regulation of DNA topoisomerase II by casein kinase II. 
  • The specificity of topoisomerase-mediated DNA cleavage defines acridine-induced frameshift specificity within a hotspot in bacteriophage T4. 
  • Tirapazamine: a hypoxia-activated topoisomerase II poison. 
  • Topoisomerase II cleavage in chromatin. 
  • Topoisomerase II levels during granulocytic maturation in vitro and in vivo. 
  • Topoisomerase II: its functions and phosphorylation. 
  • Unusual chromosome architecture and behaviour at an HSR.